Breast cancer (early) - trastuzumab: audit criteria

The audit is to assist NHS trusts to determine whether the service is implementing, and is in compliance with, the NICE technology appraisal: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer.